Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsC2c: turning cancer into chronic diseaseNickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.Management options for refractory chronic myeloid leukemia: considerations for the elderly.Molecularly targeted therapies for nonmelanoma skin cancers.Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.L-amino acid oxidase isolated from Bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect.Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.
P2860
Q27028181-2FF174AD-49A5-480F-AAC4-EC8DE964E9A8Q28657973-0C4980BB-28BA-4F48-BC93-8F8E34BA6CB4Q37440054-BC9FCD26-0CC7-4571-B577-36AEA7879E46Q38101471-D3B8E93D-1C59-4D7F-8B59-FF8203EABE48Q38107276-498DD38A-61E5-4BF3-A17B-DE3776B4FF4DQ38144200-A6F9C3B1-DDF0-48B0-927C-DEE452652D9DQ39121828-F2FD5021-BA3E-4F2F-96D4-CF10D30533D7Q39172206-B2F19C52-DFBC-4C0F-829F-C18F482EA67FQ39262510-26628660-493D-4EA3-8BE1-A500D556AF0FQ41335233-8A24A9C2-E35A-45EF-9091-698CE750BDABQ51064463-E113BBB7-66FC-4BCA-BB98-A79020E9E37EQ51066255-622C1A33-4323-4AAE-8A2E-3B6AF1C43F01Q54206519-834D378E-C086-4F5B-B18B-02E164C4CD08
P2860
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@en
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@nl
type
label
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@en
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@nl
prefLabel
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@en
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@nl
P2093
P2860
P1476
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
@en
P2093
Babu Rao Vundinti
Kanjaksha Ghosh
Shantashri Vaidya
P2860
P304
P356
10.1111/J.1600-0609.2011.01689.X
P577
2011-10-02T00:00:00Z